Multinational companies in China’s vaccine market face headwinds amid an anti-corruption crackdown and rising competition.

(Bloomberg) -- Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in ...

If you suffered losses exceeding $100,000 in Merck between February 3, 2022 and February 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at ...

Biopharma giant MSD says it stands ready to pursue new approaches to advance public health in China after its GARDASIL ...

The message was apparently designed to fit a broader push in China to boost male vaccination against HPV-related diseases following Gardasil’s local approval earlier this year in males aged 9 to 26.

Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.

The sales range reflects a decision to temporarily pause Gardasil/Gardasil 9 shipments into China beginning February 2025 through at least mid-year. The U.S. pharma giant expects adjusted EPS Of $ ...

MSD also said it would pause Gardasil sales in China until at least mid-2025. Another reason that was mentioned was weak discretionary spending. Because Gardasil is not part of China’s national ...

The drugmaker plans to temporarily pause shipments of its Gardasil vaccine to China at least through the middle of the year. Chairman and CEO Robert Davis told analysts the pause will help pare ...